121 related articles for article (PubMed ID: 35863105)
1. MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients.
Saint-Ghislain M; Derrien AC; Geoffrois L; Gastaud L; Lesimple T; Negrier S; Penel N; Kurtz JE; Le Corre Y; Dutriaux C; Gardrat S; Barnhill R; Matet A; Cassoux N; Houy A; Ramtohul T; Servois V; Mariani P; Piperno-Neumann S; Stern MH; Rodrigues M
Eur J Cancer; 2022 Sep; 173():105-112. PubMed ID: 35863105
[TBL] [Abstract][Full Text] [Related]
2. Evolutionary Routes in Metastatic Uveal Melanomas Depend on
Rodrigues M; Mobuchon L; Houy A; Alsafadi S; Baulande S; Mariani O; Marande B; Ait Rais K; Van der Kooij MK; Kapiteijn E; Gassama S; Gardrat S; Barnhill RL; Servois V; Dendale R; Putterman M; Tick S; Piperno-Neumann S; Cassoux N; Pierron G; Waterfall JJ; Roman-Roman S; Mariani P; Stern MH
Clin Cancer Res; 2019 Sep; 25(18):5513-5524. PubMed ID: 31227496
[TBL] [Abstract][Full Text] [Related]
3. Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors.
Rodrigues M; Mobuchon L; Houy A; Fiévet A; Gardrat S; Barnhill RL; Popova T; Servois V; Rampanou A; Mouton A; Dayot S; Raynal V; Galut M; Putterman M; Tick S; Cassoux N; Roman-Roman S; Bidard FC; Lantz O; Mariani P; Piperno-Neumann S; Stern MH
Nat Commun; 2018 May; 9(1):1866. PubMed ID: 29760383
[TBL] [Abstract][Full Text] [Related]
4. Germline loss-of-function variants in MBD4 are rare in Finnish patients with uveal melanoma.
Repo P; Jäntti JE; Järvinen RS; Rantala ES; Täll M; Raivio V; Kivelä TT; Turunen JA
Pigment Cell Melanoma Res; 2020 Sep; 33(5):756-762. PubMed ID: 32421892
[TBL] [Abstract][Full Text] [Related]
5. Prolonged stable disease in a uveal melanoma patient with germline MBD4 nonsense mutation treated with pembrolizumab and ipilimumab.
Johansson PA; Stark A; Palmer JM; Bigby K; Brooks K; Rolfe O; Pritchard AL; Whitehead K; Warrier S; Glasson W; Hayward NK
Immunogenetics; 2019 May; 71(5-6):433-436. PubMed ID: 30714079
[TBL] [Abstract][Full Text] [Related]
6. Role of immune checkpoint inhibitors in metastatic uveal melanoma: a single-center retrospective cohort study.
Vanaken L; Woei-A-Jin FJSH; Van Ginderdeuren R; Deroose CM; Laenen A; Missotten G; Thal DR; Bechter O; Schöffski P; Clement P
Acta Oncol; 2023 May; 62(5):480-487. PubMed ID: 37200223
[TBL] [Abstract][Full Text] [Related]
7. Germline MBD4 Mutations and Predisposition to Uveal Melanoma.
Derrien AC; Rodrigues M; Eeckhoutte A; Dayot S; Houy A; Mobuchon L; Gardrat S; Lequin D; Ballet S; Pierron G; Alsafadi S; Mariani O; El-Marjou A; Matet A; Colas C; Cassoux N; Stern MH
J Natl Cancer Inst; 2021 Jan; 113(1):80-87. PubMed ID: 32239153
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors.
Sander MS; Stukalin I; Vallerand IA; Goutam S; Ewanchuk BW; Meyers DE; Pabani A; Morris DG; Heng DYC; Cheng T
Cancer Med; 2021 Apr; 10(8):2618-2626. PubMed ID: 33724676
[TBL] [Abstract][Full Text] [Related]
9. Familial uveal melanoma and other tumors in 25 families with monoallelic germline MBD4 variants.
Villy MC; Le Ven A; Le Mentec M; Masliah-Planchon J; Houy A; Bièche I; Vacher S; Vincent-Salomon A; Dubois d'Enghien C; Schwartz M; Piperno-Neumann S; Matet A; Malaise D; Bubien V; Lortholary A; Ait Omar A; Cavaillé M; Stoppa-Lyonnet D; Cassoux N; Stern MH; Rodrigues M; Golmard L; Colas C
J Natl Cancer Inst; 2024 Apr; 116(4):580-587. PubMed ID: 38060262
[TBL] [Abstract][Full Text] [Related]
10. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
[TBL] [Abstract][Full Text] [Related]
11. Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint Inhibitors.
Kelly D; Rose AAN; Muniz TP; Hogg D; Butler MO; Saibil SD; King I; Kamil ZS; Ghazarian D; Ross K; Iafolla M; Araujo DV; Waldron J; Laperriere N; Krema H; Spreafico A
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298857
[TBL] [Abstract][Full Text] [Related]
12. Germline MBD4 deficiency causes a multi-tumor predisposition syndrome.
Palles C; West HD; Chew E; Galavotti S; Flensburg C; Grolleman JE; Jansen EAM; Curley H; Chegwidden L; Arbe-Barnes EH; Lander N; Truscott R; Pagan J; Bajel A; Sherwood K; Martin L; Thomas H; Georgiou D; Fostira F; Goldberg Y; Adams DJ; van der Biezen SAM; Christie M; Clendenning M; Thomas LE; Deltas C; Dimovski AJ; Dymerska D; Lubinski J; Mahmood K; van der Post RS; Sanders M; Weitz J; Taylor JC; Turnbull C; Vreede L; van Wezel T; Whalley C; Arnedo-Pac C; Caravagna G; Cross W; Chubb D; Frangou A; Gruber AJ; Kinnersley B; Noyvert B; Church D; Graham T; Houlston R; Lopez-Bigas N; Sottoriva A; Wedge D; ; ; ; Jenkins MA; Kuiper RP; Roberts AW; Cheadle JP; Ligtenberg MJL; Hoogerbrugge N; Koelzer VH; Rivas AD; Winship IM; Ponte CR; Buchanan DD; Power DG; Green A; Tomlinson IPM; Sampson JR; Majewski IJ; de Voer RM
Am J Hum Genet; 2022 May; 109(5):953-960. PubMed ID: 35460607
[TBL] [Abstract][Full Text] [Related]
13. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
Zhang L; Han X; Shi Y
JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
[TBL] [Abstract][Full Text] [Related]
14. [MBD4 inactivation induces a new mutator phenotype in cancers].
Rodrigues M; Mobuchon L; Houy A; Derrien AC; Stern MH
Bull Cancer; 2018 Sep; 105(9):736-737. PubMed ID: 30032956
[No Abstract] [Full Text] [Related]
15. Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors.
Zhou JG; Donaubauer AJ; Frey B; Becker I; Rutzner S; Eckstein M; Sun R; Ma H; Schubert P; Schweizer C; Fietkau R; Deutsch E; Gaipl U; Hecht M
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33593828
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitors for metastatic uveal melanoma: a meta-analysis.
Yamada K; Takeuchi M; Fukumoto T; Suzuki M; Kato A; Mizuki Y; Yamada N; Kaneko T; Mizuki N; Horita N
Sci Rep; 2024 Apr; 14(1):7887. PubMed ID: 38570507
[TBL] [Abstract][Full Text] [Related]
17. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.
Knispel S; Gassenmaier M; Menzies AM; Loquai C; Johnson DB; Franklin C; Gutzmer R; Hassel JC; Weishaupt C; Eigentler T; Schilling B; Schummer P; Sirokay J; Kiecker F; Owen CN; Fleischer MI; Cann C; Kähler KC; Mohr P; Bluhm L; Niebel D; Thoms KM; Goldinger SM; Reinhardt L; Meier F; Berking C; Reinhard R; Susok L; Ascierto PA; Drexler K; Pföhler C; Tietze J; Heinzerling L; Livingstone E; Ugurel S; Long GV; Stang A; Schadendorf D; Zimmer L
Eur J Cancer; 2021 May; 148():61-75. PubMed ID: 33735811
[TBL] [Abstract][Full Text] [Related]
18. Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma.
Zhang W; Kong Y; Li Y; Shi F; Lyu J; Sheng C; Wang S; Wang Q
Front Immunol; 2021; 12():798474. PubMed ID: 35087523
[TBL] [Abstract][Full Text] [Related]
19. Early kinetics of C reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: a multicenter cohort study.
Barth DA; Moik F; Steinlechner S; Posch F; Mayer MC; Sandner AM; Berton F; Schlintl V; Koch L; John N; Wurm R; Pichler M; Bauernhofer T; Reimann P; Wohlkönig C; Richtig E; Winder T; Preusser M; Jost PJ; Ay C; Gerger A; Terbuch A; Riedl JM
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38097343
[TBL] [Abstract][Full Text] [Related]
20. The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis.
Versluis JM; Hendriks AM; Weppler AM; Brown LJ; de Joode K; Suijkerbuijk KPM; Zimmer L; Kapiteijn EW; Allayous C; Johnson DB; Hepner A; Mangana J; Bhave P; Jansen YJL; Trojaniello C; Atkinson V; Storey L; Lorigan P; Ascierto PA; Neyns B; Haydon A; Menzies AM; Long GV; Lebbe C; van der Veldt AAM; Carlino MS; Sandhu S; van Tinteren H; de Vries EGE; Blank CU; Jalving M
Eur J Cancer; 2021 Jul; 151():72-83. PubMed ID: 33971447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
